India's largest generics drug maker Ranbaxy Laboratories reported flat earnings in the June quarter despite strong sales.

After being involved in a slugfest with US Food and Drugs Administration (US FDA), India's largest generics drug maker Ranbaxy Laboratories has some good news at last: the firm's UK subsidiary has been acquitted in a price rigging case and it has launched a generic ulcer drug in the US mar...

India's fourth largest pharmaceutical company in terms of sales, the Dilip Sanghvi-led Sun Pharmaceutical Industries has reported a whopping 24.57 percent jump in net profit for the fiscal quarter ended June 30, 2008, attributing it to strong sales.

India's second largest pharmaceutical company in terms of sales, Dr. Reddy's Laboratories has posted a 26 percent drop in net profit for the quarter ended June 30, 2008, but maintained its full-year guidance on new products launches and better sales.

A top executive of India's largest generics drug maker Ranbaxy Laboratories has blamed "vested interests," including a top pharmaceutical MNC, a leading Indian company and some stock brokers, for the downslide of the company's share prices last week.

India's top biotechnology company Biocon Ltd has teamed up with US-based Abraxis BioScience, Inc. to announce the launch of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination thera...

India's leading biotechnology major Biocon Ltd reported a 72 percent fall in its net profit for the fiscal quarter ended June 30, 2008.

A top executive of India's largest generics drug maker Ranbaxy Laboratories has allayed fears that its $4.6 billion takeover deal with Japanese drug maker Daiichi Sankyo is in jeopardy, saying that the deal is very much "on track."

The United States Food and Drug Administration (US FDA) has accused India's largest generics drug maker, Ranbaxy Laboratories, of forging and concealing documents relating to an investigation into the quality of the company's drugs sold in the US market and has filed a motion in the distri...

India's leading healthcare services provider Max India Ltd said it has partnered with UK's BUPA Finance Plc for setting up a health insurance company in India.

India's second largest pharmaceutical company in terms of sales, Dr. Reddy's Laboratories, said, Tuesday, it has signed a global distribution agreement for painkiller and anti-inflammatory drug Ibuprofen API with Albemarle Corporation.

Mumbai-based Glenmark Pharmaceuticals Ltd said it has bought seven drug brands in Poland from Iceland's Actavis and its Polish affiliate Biovena.

Glenmark Generics Ltd, a unit of India's Glenmark Pharmaceuticals Ltd, has received the nod from the US Food and Drug Administration (USFDA) for the sale of its generic version of anti-hypertension drug, Trandolapril.

India's largest generics durgmaker Rnbaxy Laboratories, which has agreed to become a subsidiary of Japanese drugmaker Daiichi Sankyo for $4.6 billion, pulled off a coup of sorts, announcing it has settled certain patent disputes with Pfizer over its $13 billion blockbuster anti-cholesterol drug...

The battle for acquisition of India's largest generics drugmaker Ranbaxy Laboratories is hotting up with rumors making the round that German pharmaceutical major Pfizer may make a hostile bid to counter Japanese drugmaker Daiichi Sankyo's $4.6 billion offer.

In what is seen as India's biggest acquisition deal in the pharmaceutical sector, Japanese drugmaker Daiichi Sankyo Co. said it has reached an agreement with India's largest generics drugmaker Ranbaxy Laboratories Ltd. which will see the former acquire the latter's majority stake for ...

Chennai-based business group Trivitron has roped in international partners to give India her first Medical Technology Park (MTP).

India's leading biotechnology company, Biocon Ltd. has posted a 12.5 percent rise in net profit for the fiscal year ended March 31, 2008, and has boosted market confidence by saying it expects good returns on its investment in the coming years.

India's top drugmaker in terms of sales, Ranbaxy Laboratories has posted a 7 percent rise in net profit for the fiscal month ended March 31, 2008, helped by sales of generic drugs, and boosted investors' confidence by forecasting improved performance over the rest of the year.